Frontier mental health research: psychedelics & drug studies

Key findings

• Some small clinical trials and older studies report that LSD and other classic psychedelics reduced symptoms of low mood and depression for weeks or months in some people. ^{15135 15055 15060 15063}
• Overall evidence is limited: many studies are small, early-stage, or use different drugs and methods, so we cannot be certain how well LSD works for most people yet. ^{15078 15070 15085 15063}
• When given in carefully controlled medical settings with therapy, trials of psychedelics have generally reported acceptable short-term safety and benefits, but this is not the same as proving long-term safety in wider use. ^{15135 15055 15085}
• Some psychedelic medicines (for example ibogaine) carry serious medical risks in some people, so safety varies by drug and requires close monitoring; LSD trials under research conditions did not show the same high risk signal as ibogaine. ^{15050 15085 15135}
• Non-drug factors matter a lot: preparation, the physical and social setting, and follow-up therapy shape whether people get benefit and help keep them safe. ^{15086 15065 15063 15092}
• Lab and animal studies show classic psychedelics can increase brain plasticity — meaning brain cells grow new connections — and theory (REBUS) says psychedelics can loosen rigid thinking patterns; but human biological markers are inconsistent. ^{15050 15135 15091 15129}
• There are gaps in who has been studied: many trials enrolled mostly white participants, so we don’t know if results apply equally across different ethnic and cultural groups. ¹⁵⁰⁹⁵